Attribution is the analytical process that answers the most consequential question in pharmaceutical marketing: which of our channels and campaigns actually drove the prescribing outcomes we care about? The answer determines how we allocate budgets, which channels we invest in, and which we sunset. Get attribution right, and every marketing dollar works harder. Get it wrong, and you systematically misallocate millions of dollars annually, over-investing in channels that appear effective under a flawed model while under-investing in channels that are actually driving conversions.
The choice between first-touch and multi-touch attribution is not merely a technical decision. It is a strategic one that shapes how your organization understands channel effectiveness. First-touch attribution tells you which channels are best at generating initial awareness. Last-touch attribution tells you which channels are closest to the prescribing decision. But neither tells you the full story. Multi-touch attribution attempts to distribute credit across all contributing channels, providing a more complete (though more complex) picture of what actually drives HCP prescribing behavior.
This article provides a comprehensive comparison of six attribution models, with a detailed worked example showing how the same HCP journey gets credited differently under each approach. It also includes a practical implementation guide for pharmaceutical marketing teams.
The Core Problem: Credit Assignment
Consider a typical HCP journey in specialty pharmaceuticals. Dr. Martinez, a community gastroenterologist, encounters your brand through the following sequence of interactions over a four-month period:
- January 5: Sees a Doximity-sponsored article about your product's mechanism of action (Digital NPP)
- January 18: Receives an approved email with Phase III efficacy data, opens it, and clicks through to the clinical data summary (Approved Email)
- February 2: Receives a second approved email with patient selection criteria, opens it (Approved Email)
- February 20: Attends a webinar on real-world evidence for your product, stays for 45 minutes, asks two questions during Q&A (Webinar)
- March 5: Rep visit during which Dr. Martinez discusses patient selection and receives a sample starter kit (Rep Detail + eSampling)
- March 22: Receives an RTE follow-up from the rep with dosing guidelines and patient support resources (RTE)
- April 10: Writes her first prescription for your product (Conversion: NRx)
Seven distinct touchpoints across five channels contributed to this conversion. The fundamental question of attribution is: how much credit does each touchpoint deserve for Dr. Martinez's first prescription? The answer depends entirely on which attribution model you use, and the differences are not trivial.
Six Attribution Models: A Worked Comparison
Let us apply six different attribution models to Dr. Martinez's journey and observe how the credit distribution changes. For simplicity, we will express attribution as a percentage of total credit for the conversion.
1. First-Touch Attribution
First-touch assigns 100% of the credit to the first interaction in the journey.
| Channel | Touchpoint | Credit |
|---|---|---|
| Digital NPP | Doximity article (Jan 5) | 100% |
| Approved Email | Two sends (Jan 18, Feb 2) | 0% |
| Webinar | Attendance (Feb 20) | 0% |
| Rep Detail + eSampling | Visit + sample (Mar 5) | 0% |
| RTE | Follow-up (Mar 22) | 0% |
Verdict: First-touch credits the Doximity ad with the entire conversion. This model is useful if your primary objective is understanding which channels generate initial awareness, but it completely ignores the six subsequent interactions that built Dr. Martinez's clinical confidence and facilitated the trial. In pharma, where prescribing decisions require multiple exposures to clinical data, first-touch is rarely appropriate as a standalone model.
2. Last-Touch Attribution
Last-touch assigns 100% of the credit to the final interaction before conversion.
| Channel | Touchpoint | Credit |
|---|---|---|
| Digital NPP | Doximity article (Jan 5) | 0% |
| Approved Email | Two sends (Jan 18, Feb 2) | 0% |
| Webinar | Attendance (Feb 20) | 0% |
| Rep Detail + eSampling | Visit + sample (Mar 5) | 0% |
| RTE | Follow-up (Mar 22) | 100% |
Verdict: Last-touch credits the rep's follow-up email with the entire conversion. This is the most common attribution model in pharma today, and it systematically over-credits whichever channel happens to be last in the sequence. In this case, the RTE was certainly important (it reinforced the clinical messaging and provided practical resources), but it was the capstone on a journey built by digital, email, webinar, and rep interactions. Crediting it with 100% of the conversion is as misleading as crediting only the Doximity article.
The Field Force Bias: In practice, last-touch attribution in pharma overwhelmingly credits the field force because rep visits and rep-triggered emails are frequently the last channel interactions before a prescription. This creates a self-reinforcing cycle: last-touch says reps drive the most conversions, so reps get the most budget, so reps make more visits, so they appear in even more last-touch positions, so they get even more credit. Breaking this cycle requires multi-touch attribution.
3. Linear Attribution
Linear attribution distributes credit equally across all touchpoints. Dr. Martinez had seven touchpoints (counting the two approved emails separately), so each receives approximately 14.3% of the credit.
| Channel | Touchpoints | Credit |
|---|---|---|
| Digital NPP | 1 impression | 14.3% |
| Approved Email | 2 sends | 28.6% |
| Webinar | 1 attendance | 14.3% |
| Rep Detail + eSampling | 1 visit + sample | 14.3% |
| RTE | 1 send | 14.3% |
| Source: Rep Detail | (within Rep + Sample) | ~7.1% |
| Source: eSampling | (within Rep + Sample) | ~7.1% |
Verdict: Linear attribution is more equitable than first-touch or last-touch because it acknowledges every channel's contribution. However, it treats all touchpoints as equally important, which they clearly are not. A passive Doximity ad impression that Dr. Martinez may have barely noticed receives the same 14.3% credit as a 45-minute webinar where she actively asked questions. The rep visit where she received a sample and had a detailed clinical conversation receives the same credit as each individual email send. This equal-weighting limitation makes linear attribution a useful reference point but rarely the best primary model.
4. Time-Decay Attribution
Time-decay attribution assigns more credit to touchpoints closer to the conversion event. Using a standard 14-day half-life, each touchpoint's credit is weighted based on its proximity to the April 10 prescription.
| Channel | Date | Days to Conversion | Weight | Credit |
|---|---|---|---|---|
| Digital NPP | Jan 5 | 95 days | Low | ~3% |
| Approved Email #1 | Jan 18 | 82 days | Low | ~4% |
| Approved Email #2 | Feb 2 | 67 days | Low-Medium | ~6% |
| Webinar | Feb 20 | 49 days | Medium | ~10% |
| Rep Detail + eSampling | Mar 5 | 36 days | Medium-High | ~18% |
| RTE | Mar 22 | 19 days | High | ~59% |
Verdict: Time-decay produces a dramatically skewed distribution that heavily favors the most recent touchpoints. The RTE receives nearly 60% of the credit simply because it was the last action before the prescription, while the Doximity article and first email that initiated Dr. Martinez's journey receive negligible credit. This model may be appropriate for therapeutic areas where recent events are the primary prescribing triggers, but for most specialty products where clinical familiarity builds over months, time-decay systematically undervalues the awareness-building and education phases of the journey.
5. Position-Based (U-Shaped) Attribution
Position-based attribution assigns 40% of credit to the first touchpoint, 40% to the last touchpoint, and distributes the remaining 20% equally among all intermediate touchpoints.
| Channel | Position | Credit |
|---|---|---|
| Digital NPP | First touch | 40% |
| Approved Email | Middle (2 touchpoints) | 6.7% each (13.3% total) |
| Webinar | Middle | 6.7% |
| Rep Detail + eSampling | Middle | 6.7% |
| RTE | Last touch | 40% |
Verdict: Position-based attribution provides a more balanced view than the previous models. It appropriately credits both the Doximity ad (which initiated Dr. Martinez's awareness) and the RTE (which provided the final practical nudge), while also allocating meaningful credit to the intermediate channels that built clinical confidence. The webinar, which was a high-engagement touchpoint, receives only 6.7%, which may undervalue its contribution. The rep visit with sample delivery, arguably the most influential mid-journey event, also receives only 6.7%. The 40/20/40 split is a reasonable default but may not reflect the true influence distribution.
6. Data-Driven (Algorithmic) Attribution
Data-driven attribution uses statistical models to estimate each channel's actual contribution based on observed conversion patterns. Unlike the rule-based models above, it does not assume a predetermined credit distribution. Instead, it analyzes thousands of HCP journeys to identify which channels and sequences are most strongly associated with prescribing conversion.
The specific credit allocation depends on the model (common approaches include Markov Chain, Shapley Value, and logistic regression), but a typical data-driven result for Dr. Martinez's journey might look like this:
| Channel | Estimated Credit | Reasoning |
|---|---|---|
| Digital NPP | 8% | Initiated awareness but low engagement depth |
| Approved Email | 15% | Two engaged touchpoints delivering clinical content; email engagement is a strong mid-funnel predictor |
| Webinar | 25% | Highest engagement depth (45 min, active Q&A); model identifies webinar attendance as the strongest mid-journey conversion predictor |
| Rep Detail + eSampling | 30% | Personal interaction with clinical discussion + physical trial enabler; model estimates this as the highest single-channel contributor |
| RTE | 12% | Timely reinforcement but lower incremental impact than the preceding rep visit |
| Unattributed / Baseline | 10% | Conversion would have occurred at some probability without any marketing (baseline propensity) |
Verdict: Data-driven attribution produces the most empirically grounded credit distribution. In this example, it identifies the rep visit (30%) and webinar (25%) as the two most influential touchpoints, which aligns with the clinical intuition that personal interactions and deep educational engagements are the strongest prescribing drivers. It also allocates meaningful credit to the email campaign (15%) for its role in building clinical familiarity and moving Dr. Martinez toward the webinar and rep visit. The digital ad receives modest credit (8%) as an awareness initiator but not a conversion driver. And notably, it reserves 10% for baseline propensity, acknowledging that some HCPs would have prescribed regardless of marketing activity.
The Key Insight: Look at how dramatically the credit distribution changes across models. Digital NPP receives 100% (first-touch), 0% (last-touch), 14.3% (linear), 3% (time-decay), 40% (position-based), or 8% (data-driven). The rep visit receives 0% (first-touch), 0% (last-touch), 14.3% (linear), 18% (time-decay), 6.7% (position-based), or 30% (data-driven). These are not minor differences. They would lead to fundamentally different budget allocation decisions. This is why the choice of attribution model is one of the most impactful decisions a marketing analytics team makes.
Side-by-Side Comparison
| Channel | First-Touch | Last-Touch | Linear | Time-Decay | Position-Based | Data-Driven |
|---|---|---|---|---|---|---|
| Digital NPP | 100% | 0% | 14.3% | 3% | 40% | 8% |
| Approved Email | 0% | 0% | 28.6% | 10% | 13.3% | 15% |
| Webinar | 0% | 0% | 14.3% | 10% | 6.7% | 25% |
| Rep + Sample | 0% | 0% | 14.3% | 18% | 6.7% | 30% |
| RTE | 0% | 100% | 14.3% | 59% | 40% | 12% |
Practical Implementation Guide
Step 1: Start With What You Have
Most pharmaceutical marketing teams already have the data needed to implement basic multi-touch attribution. At minimum, you need CRM call data (Veeva), email engagement data (Veeva Vault or equivalent), and prescription data (IQVIA Xponent or equivalent). These three sources cover the most important channels and allow you to build a unified interaction log linked by HCP identifier.
Do not wait for perfect data integration before starting. Build the HCP crosswalk between your CRM and Rx data, implement a simple attribution model (start with position-based), and begin generating insights. You can progressively add digital, webinar, and event data as your data infrastructure matures.
Step 2: Run Multiple Models in Parallel
Never rely on a single attribution model. Run at least three models (last-touch as baseline, position-based as a balanced rule-based approach, and one advanced model) in parallel and compare the results. The areas where all models agree represent high-confidence findings. The areas where models disagree represent uncertainty that should be resolved through incrementality testing.
Step 3: Validate With Incrementality Testing
The gold standard for validating attribution results is geographic holdout testing. Select matched pairs of geographic regions (e.g., two similar DMAs or states). In one region, reduce or eliminate a specific channel. In the other, maintain the current investment. Measure the difference in prescribing outcomes. If your attribution model says Channel X contributes 15% of conversions, and removing Channel X in a holdout region produces a 13-17% decline, your model is well-calibrated. If the holdout shows a 5% decline, your model is over-crediting that channel.
Step 4: Use Attribution for Decisions, Not Just Reporting
The purpose of attribution is not to produce a report that gets filed away. It is to inform budget allocation decisions. Use the attribution results to build a channel contribution model that estimates how prescribing outcomes would change under different budget scenarios. When the brand director asks "what happens if we move $2 million from the field force to digital?", your attribution model should be able to simulate the answer.
Step 5: Refresh Quarterly
Channel effectiveness changes over time as the competitive landscape evolves, HCP familiarity grows, and the brand moves through its lifecycle. Attribution models should be refreshed quarterly with the latest 12 months of data to capture these shifts. An annual refresh is too infrequent to inform mid-year budget adjustments.
When to Use Each Model
| Model | Best Use Case | When to Avoid | Minimum Data Required |
|---|---|---|---|
| First-Touch | Launch brands measuring awareness generation; upper-funnel channel evaluation | Mature brands; any brand making budget allocation decisions based on full-funnel contribution | CRM + Rx |
| Last-Touch | Quick baseline; measuring which channels are closest to conversion; sales-aligned reporting | Any scenario where field force over-crediting would lead to poor budget decisions | CRM + Rx |
| Linear | Baseline comparison; new attribution teams getting started; reporting to stakeholders unfamiliar with attribution | Scenarios where touchpoint quality varies dramatically (high-value rep visit vs. passive ad impression) | CRM + email + Rx |
| Time-Decay | Brands where recent events are the primary conversion trigger; therapeutic areas with short decision cycles | Specialty or rare disease brands with long decision journeys; brands where early clinical education is critical | CRM + email + digital + Rx |
| Position-Based | Default recommendation for most pharma brands; balanced view of awareness and conversion | When you have sufficient data for algorithmic attribution (upgrade to data-driven) | CRM + email + digital + events + Rx |
| Data-Driven | Brands with 12+ months of unified data across 4+ channels; teams ready for algorithmic decision-making | Teams without data science support; brands with insufficient data volume for statistical modeling | All channels unified + 12-18 months historical |
The Baseline Propensity Problem
One of the most overlooked aspects of pharmaceutical attribution is baseline prescribing propensity. Some HCPs would have prescribed your product regardless of any marketing activity because of patient demand, formulary position, or clinical familiarity with the therapeutic class. If your attribution model credits marketing channels for 100% of conversions, it is over-crediting marketing by the baseline propensity rate.
For established brands in competitive therapeutic areas, baseline propensity (the percentage of HCPs who would have prescribed without any marketing contact) can range from 10-30%. For novel therapies in new categories, baseline propensity is typically lower (5-15%). Data-driven attribution models can estimate baseline propensity directly. Rule-based models cannot, which is another reason why they tend to over-credit marketing channels.
Practical Recommendation: If you are using rule-based attribution (first-touch, last-touch, linear, position-based, or time-decay), discount the channel contribution estimates by an estimated baseline propensity of 15-20%. This provides a more conservative and realistic view of marketing's true incremental impact. If your attribution model says channels contributed $50 million in revenue, a 15% baseline propensity adjustment means the true incremental marketing contribution is approximately $42.5 million.
Conclusion
There is no perfect attribution model. Every model makes assumptions and tradeoffs. First-touch and last-touch are simple but misleading. Linear is equitable but ignores influence differences. Time-decay captures recency effects but discounts foundational touchpoints. Position-based is a balanced starting point but relies on arbitrary weightings. Data-driven is the most accurate but requires significant data and analytical investment.
The right approach is not to choose one model but to use multiple models in concert. Run last-touch as a baseline that everyone understands. Run position-based as a balanced alternative. Progress toward data-driven as your data and analytical capabilities mature. And validate every model's findings with incrementality testing to close the gap between correlation and causation.
The pharmaceutical brands that will win the next decade of competition are not those with the largest marketing budgets or the most creative campaigns. They are the ones that can most accurately measure which marketing investments actually drive prescribing behavior, and continuously optimize their channel mix based on that understanding. Attribution is the foundation of that capability, and every day your team operates without a proper multi-touch attribution model is a day you are making multi-million-dollar budget decisions on incomplete information.